On January 18, 2023, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the National Medical Insurance, Labour Injury Insurance and Maternity Insurance Essential Drug List (2022) [hereafter referred to as the National Essential Drug List (2022)], and an exclusive patented product, anti-HIV long-acting fusion inhibitor AIKENING® (generic name: Albuvirtide) by Frontier Biotechnologies (Nanjing) Co., Ltd. (hereinafter referred to as the Company, stock code: 688221.SH), , successfully renewed into the National Essential Drug List (2022). 

The successful renewal of the National Essential Drug List (2022) will not only maximizing the local commercialization potential of the Company, but also expected to continue optimizing the clinical advantages and scarcity value of the product. AIKENING® continues to benefit HIV/AIDS patients, reducing the financial burden and greatly improve the affordability and accessibility for needy patients.